Active Hexose Correlated Compound (AHCC)

Shiitake-derived alpha-glucan that activates NK/T cells, cytokines; adjunct benefits in human cancer trials.

AI extractedhuman reviewedsources checkedretractions suppressed

👥⭐⭐⭐ Moderate — Preliminary RCTs/cohorts in HCC (improved survival), pancreatic/ovarian (reduced toxicities, immune boost); strong mechanistic/preclinical data; larger oncology trials needed.Active Hexose Correlated CompoundShiitake mycelia extract

Forms: Standardized AHCC capsules (1g per 2-3 caps) · Powder form

Educational only, not medical advice. OncoForge makes no claim that Active Hexose Correlated Compound (AHCC) treats, prevents, or cures any condition, beyond what the linked studies show. Evidence levels vary; effects may not translate to people, and some compounds can cause harm. Always coordinate with your oncology team.

Simple Summary

AHCC, a shiitake mushroom extract, supercharges your immune system's NK and T-cells to better spot and destroy cancer cells. It also nudges tumors toward self-destruction and teams up with chemo to make it more effective while easing side effects like nausea or low blood counts. Human studies show promise for liver, pancreatic, and ovarian cancers, especially as an add-on to standard treatments.

Evidence at a glance

Tier 3 · early humanHepatocellular carcinomaPancreatic ductal adenocarcinomaOvarian cancer

Strong preclinical; preliminary human data as chemo adjunct in liver/pancreatic/ovarian cancers.

How it may work

AHCC is a proprietary alpha-glucan-rich extract from cultured shiitake (Lentinula edodes) mycelia, with low-molecular-weight polysaccharides (primarily alpha-1,4-glucans with alpha-1,3 branches, ~5 kDa). It modulates immunity by priming Toll-like receptors (TLR2/TLR4) on intestinal epithelium and immune cells, enhancing dendritic cell maturation, NK cell cytotoxicity, and T-cell (CD4+/CD8+) proliferation. This leads to upregulated cytokine production (IL-12, IFN-γ, TNF-α) and nitric oxide regulation. Anticancer effects include induction of tumor cell apoptosis (Bax↑/Bcl-2↓, caspase-3/7 activation), overcoming multidrug resistance via downregulation of Heat Shock Factor 1 (HSF1) and HSP27, and synergy with chemotherapy (e.g., gemcitabine, 5-FU) by improving drug efficacy and reducing toxicities. It also exhibits anti-inflammatory and antioxidant properties, protecting against oxidative stress and chemo-induced adverse events. Pharmacokinetically, AHCC is well-absorbed orally with good bioavailability, peaking in 1-2h and exerting systemic immune effects.

Targets & pathways

Curated mechanistic targets reported for this agent — how it may act on cells, not proof of a clinical effect.

Immune↑Innate and adaptive enhancement
NK cell activation↑Cytotoxicity ↑ via IL-12/IFN-γ
T-cell response↑
Cytokines↑IFN-γ, IL-12, TNF-α
Apoptosis (cancer cells)↑
Tumor growth↓Preclinical inhibition

NK ↑T-cell ↑Cytokines ↑Apoptosis ↑Immune modulationTumor growth ↓

Often studied / combined with

Combinations reported in the literature, not a protocol or a recommendation.

Chemotherapy: Enhances antitumor effects, reduces side effects in human studies.
Immunotherapy (PD-1/CTLA-4): Promotes tumor suppressive effects in preclinical models.

Overlapping mechanisms

Immune ↑, NK Activation: Limit concurrent strong NK boosters in sensitive patients.

Safety & interactions

Severity and how well-established each signal is are shown separately. Verify everything with your oncologist or pharmacist — absence here does not mean safe.

Risk categories

Diarrhea RiskImmunostimulant Autoimmune CautionPregnancy Avoid

Potential interactions

CYP2D6 substrates (e.g., doxorubicin)MonitorModerateTheoreticalAHCC induces CYP2D6, may reduce drug levels.
chemotherapyMonitorTheoreticalPotential to enhance efficacy or reduce side effects; coordinate.
aromatase inhibitorsMonitorMildTheoreticalMay induce aromatase, reducing inhibitor efficacy.

Timing

Empty stomach
AM
PM

References

Research

No published studies for Active Hexose Correlated Compound (AHCC) yet

New studies appear here once they’ve been reviewed. Browse all studies.

Dose: as studied, not a recommendation

These are doses as studied or reported, never a recommendation. The right amount of Active Hexose Correlated Compound (AHCC) depends on you, your other medicines, and your situation; decide it with your oncology team and pharmacist, not from a web page.

Ranges seen in adjunct / practice use: 3–6 g (oral) 3-6 g/day divided BID-TID; on empty stomach preferred for absorption, 3g/day in liver cancer study; up to 6g/day in pancreatic. Manufacturer recommends 3g/day max; divide doses..

Trials studying Active Hexose Correlated Compound (AHCC)

No actively-recruiting trials matched right now. Recruiting is not the same as proven. Search ClinicalTrials.gov →

Inclusion here is not an endorsement. OncoForge makes no claim beyond what the linked studies show. Discuss anything on this page with your oncology team before acting on it.

← All agents · Research Radar